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ABSTRACT
The presence of Cu(II) in penicillin and cephalosporin solutions,
has been proved, to promote in vitro the antibiotic degradation to
the corresponding acid derivates. HPLC studies provided an
additional evidence for the reaction mechanism. The mechanisms of
Cu(II) catalysis involve a ternary complex. This work was undertaken
to study the consequences of this degradation in vivo upper the
pharmacokinetic, pharmacodynamic and activity of the antibiotic
cefotaxime. It is one of the most used «third-generation»
cephalosporin in the world, this is because of that the interaction
cefotaxime-metal deserved our attention. Our results remarked a
lower concentration of free cefotaxime in blood, liver, spleen, kidney,
lung and heart in organs from animals suffering Cu-intoxication.
The differences more significant between intoxicated and control
rats were observed in liver, lung and kidney. In addition cefotaxime
linked to copper lose most of the microbicidal activity against
bacterial strains of Bacillus subtilis CECT 356, Escherichia coli CECT
434, Escherichia coli CECT 616, Staphilococus aureus spp aureus
CECT 435, Staphilococus aureus spp aureus CECT 239, in plate tests.
It means that cefotaxime would become ineffective as antibiotic in
metal poisoned patients.
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RESUMEN
Interacción in vivo del Cu(II) con cefotaxima
Este trabajo estudia la reacción del cobre II con una cefalospo-
rina, la cefotoxima, in vivo; los mecanismos catalíticos que implican
la presencia de complejos ternarios, su farmacocinética y su farma-
codinamia que afectan a la actividad del antibiótico. Las diferencias
más significativas entre las ratas intoxicadas y control fueron obser-
vadas en riñón, pulmón e hígado. También hemos estudiado la ac-
tividad microbicida en Bacillus subtilis CECT 356, Escherichia coli
CECT 434, Escherichia coli CECT 616, Staphilococus aureus spp
aureus CECT 435, Staphilococus aureus spp aureus CECT 239.
Palabras clave: Cobre(II); Cefotaxima; Farmacodinamia; Farma-
cocinética; HPLC.
1. INTRODUCTION
The transition metal interactions to penicillins (1-5) and
cephalosporins (6) were studied previously by spectrophotometric
and potentiometric methods. In the case of cefotaxime, as impurity,
also for HPLC (7).
In those studies it was observed that the effect of Cu(II) on the
penicillins and cephalosporins was to promote their degradation to
coordination complexes of Cu(II) and the corresponding penicilloic
and cephalosporanic acids, (see Figure 1). Other authors have studied
the formation of the complex in vitro between Cu(II) and penicillins
and cephalosporins, by means of the reaction mechanisms,
evaluating the stability constants for the interaction between Cu(II)
and these antibiotics (2, 6).
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Figure 1. Mechanism of the hydrolytic reaction of Cefotaxime with addition of
Copper.
This communication stresses in how the formation of the complex
between Cu(II) and cefotaxime affects on the concentration,
distribution and stability of this cephalosporin. The importance of
the formation of this complex stems from the lowest concentration
of free cefotaxime in blood and organs only when takes place
intoxication. This free-antibiotic concentration could be lower than
the administration of the antibiotic required killing the micro-
organism that causes the infection.
We compared the concentration, distribution and stability of the
free cefotaxime in rats without toxic with poisoned rats, after 30, 60,
90, 120, 150, 180 and 210 min. after administrating this antibiotic.
This comparison was achieved by measuring the concentration of
free cefotaxime in blood, liver, spleen, kidney, lung and heart
homogenates of poisoned rats and rats without the toxic. The
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methodology applied for this purpose was HPLC since this technique
facilitates the separation of the complex Cu(II)cefotaxime, the
corresponding Cu(II)-cephalosporanic acid chelate, free cefotaxime
and their compounds resulting from the degradation of cefotaxime.
This paper is also focused on how much microbial activity
contains the compounds produced from the complexation metal-
cefotaxime. In pursuit of that aim, we studied the biological activity
of the complexes against Bacillus subtilis CECT 356, Escherichia coli
CECT 434, Escherichia coli CECT 616, Staphilococus aureus spp
aureus CECT 435 and Staphilococus aureus spp aureus CECT 239
compared to data from experiments with free cefotaxime and Cu(II)
at physiological concentrations found in poisoned living beens.
This work should be a clue to reveal whether the complex
antibiotic-metal loses the microbiological activity as would be
hypothesised by former works done in in vitro conditions.
2. MATERIALS AND METHODS
2.1. Biology materials
Seventy five Wistar rats males of 250 to 300g weight were used
throughout this work and supplied by the warehouse of the
Complutense University of Madrid.
Animals were maintained in one of the rats room of the
warehouse. The temperature was 20 ºC, the relative humidity was
55% and the intensity of the light inside the room was 400 LUX
using cycles of 12 hours of light/darkness.
Animals were distributed by groups in order to assay different
treatments. One group of 35 rats with copper (group A), which was
poisoned with a nasogastric sound administering to their everyday 4
mL of a solution of 4 mg/mL of a copper (II). monohydrate. acetate
during 8 days. The groups left were arranged one of them with 35
rats  (group B), and the other one with 5 rats (group C), both of
them without metal.
Groups A and B were put under treatment with an intramuscular
administration of an only dose of 200 mg of cefotaxime.
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Group C was used as a control to know the different substances
which belonged to the animals in order to not to be confusing with
the free cefotaxime throughout the study.
Five rats of the groups A and B, were sacrificed after 30, 60, 90,
120, 150, 180 and 210 minutes after the antibiotic administration.
The blood, liver, spleen, kidney, lung and heart of those rats were
extracted and after that, they were measuring their free cefotaxime
concentration by HPLC.
Residual microbicide activity was tested by antibiogram
experiments  in agar plates using bacteria strains from the CECT
(Spanish Type Culture Collection, Burjasot, Spain). Those strains
were Escherichia coli CECT 434 = ATCC 25922, described as standard
for sensibility, Escherichia coli CECT 616 = ATCC 8739, described
for assays with liquid with metal, Staphilococus aureus spp aureus
CECT 435, Staphilococus aureus spp aureus CECT 239 = ATCC 6538
and Bacillus subtilis CECT 356 = ATCC 6633 as «a priori» negative
control since the species was not listed among the affectable bacteria
by cefotaxime.
The strains were maintained in TSA media at refrigeration
teemperature and precultured in tubes with 10 mL TSB medium at
37 ºC for 24 hours before the experiments.
2.2. Chemical and reagents
Cefotaxime sodium was supplied by the Teaching Hospital of
Madrid. Copper (II) acetate was obtained from Merck. Trichloracetic
acid was supplied by Scharlau, this substance was used in
concentrations of 10% and 20%.
The mobile phase reagents used were HPLC grade methanol from
Scharlau. Water used was from a Milli-Rho-Milli-Q system
(Millipore, Bedford, MA, USA). Phosphate buffer (0.1 M) was
prepared with phosphate monopotasic anhydride and o phosphoric
acid supplied by Merck.
The agar media used were TSA, a general bacterial growth media,
and blood agar, both cooked as recommended the Merck’s recipes.
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2.3. Apparatus and instrument
Kontron high-pressure liquid chromatograph equipped with a
Kontron 420 pump. An automatic injector with 6 valves Kontron
Auto Sampler 460. A variable-wavelength UV detector of Kontron
Uvikon 735 LC. Phenomenex C18 column (25 x 0.46 cm), fulled with
particles of 5 mm, besides this column of separation, a precolumn
and a protective column fulled with the same material that the first
column were used. A Kontron Station Data with D450 software was
used to control the detector and injector, on the other hand it allowed
the integration of the chromatogram peaks and it cuantificated the
results.
Paper Whatman discs, discs AA of 7 mm diameter were used to
absorb the antibiotic solutions in the agar-plate experiments.
2.4. Analytical procedure
The extraction of cefotaxime in blood was carried out by means
of protein precipitants in 10% trichloroacetic acid (8) 1.5 mL of this
reagent was added to 0.5 mL of blood. This mixture was centrifuged
at 3000 rpm for 5 min. The supernatant was collected through a
Pasteur pipet and filtered through MFS disks of nylon of 0.4 mm of
diameter. The clean supernatant was assayed by HPLC.
The extraction of cefotaxime in organs such as liver, spleen,
kidney, lung and heart, was carried out by means of trichloroacetic
acid 20%. 2 mL of this reagent were added to 0.5 g of dry weight of
each organ. Each mixture was done homogeneous and was
centrifuged at 3000 rpm for 10 min. The supernatant was collected
through a Pasteur pipet and filtered through MFS disks of nylon of
0.4 mm of diameter. It was later assayed by HPLC.
Isocratic HPLC conditions used along this wak were: the mobile
phase consisted of a 20:80% solution (v/v) of methanol in 0.01 M
PO4H2K. The pH of the final solution was adjusted to 3.2 with
phosphoric acid. The flow rate was 1 mL/min. Chromatograph was
loaded with 40 μL of each sample. Chromatograms were run at room
temperature. Samples were detected at 254 nm.
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The susceptibility tests were as follows: One loop of each of the
precultured strains was spread on to the whole surface of agar-plates.
Immediately after the inoculation paper discs soaked with 20 ìL of
the assays solutions were placed on to the agar media. The plates
were kept in the fridge for 30 minutes to allow the liquid diffusion
through out the agar media while the bacterial growth was arrested.
Finally the plates were cultured for one day at 37 ºC and the
microbicide effect of the solutions were measured by the size of the
diameter of  the growth inhibition zone (GIZ) surrounding each disc.
The assayed liquids were: free metal, free cefotaxime and the
complex metal-antibiotic.
Standard solutions of free cefotaxime was prepared based on the
Minimal Inhibitory Concentration (MIC) reported in literature (9),
being the solutions 5 times over the MIC of each species: for S.
aureus spp aureus and E. coli, the MICs were 3.3 μM and 0.12 μM
respectively. In the assays with B. subtilis, since it was assumed to
be unsensitive to the antibiotic, the mother solution was as in S.
aureus spp aureus.
The highest concentrations of free metal assayed dissolved in
water wee 5 times the maximum amount of Cu(II) found by us in
poisoned rats (10). The source of Cu(II) was obtained from the
acetate monohydrate salt at 44 μM.
To measure the activity of the complex antibiotic-metal was
necessary one previous procedure to isolate the antibiotic bounded
to copper. Free antibiotic and the metal salt were dissolved together
at saturation, 0.4 M for both components, at room temperature to
promote the complexation reaction. The complex was separated from
the residual contamination by chromatophy in a HPLC column
exactly as the conditions as we identified the free cefotaxime in rats.
The chromatografied buffer containing the complex was collected in
1.5 ml eppendorfs.
The resulting complex was dissolved in a methanol buffer. To
prevent the methanol toxicity, the alcohol was removed by
dissecation in a vacuum trap. The final power debris was weighted,
resuspended in water at saturation, homogenized and pooled. The
dry amount of the complex antibiotic-Cu was 90 mg. We assumed all
the dry weight to be the complex since the phosphate coeluted from
the isolation buffer was negligible (5 μg).
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The aqueous complex was prepared extemporarely at room
temperate yielding 0.66 M cefotaxime-Cu final concentration. The
assays were done with this concentration and four other more diluted
in water.
3. RESULTS AND DISCUSSION
3.1. Concentration of cefotaxime
The concentration homogenates of free cefotaxime was measured
in blood, liver, kidney, spleen, lung and heart of the killed rats from
groups A and B at the 30, 60, 90, 120, 150, 180 and 210 min. after
the administration of cefotaxime. As there were 5 rats by each time,
the average concentration of free cefotaxime was calculated by each
group of 5 rats that were killed at each time.
Free antibiotic was present in all of samples showing a peak after
30 min of the administration the highest concentration of cefotaxime
was found in blood (four order of magnitude more cefotaxime than
the solid organs).
After the first 30 min, the antibiotic concentration dropped from
the maximum to the minimal values reached after 3 hours and half
of the beginning of the experiment.
The declining plots depicted a «two-phase» kinetic, inespectively
of the group of rats or the organ source of the samples, in good
agreement with the conclusion of the decrease of free antibiotic
found in adult humans with normal renal function (11, 12).
In the first 30-90 min cefotaxime disappeared from the sample
slowly, afterwards the declining late accelerated.
We can establish conclusive results describing that the amount of
antibiotic is much higher in control rats than in copper-toxified rats.
The differences more significant have been seen in liver, kidney
and lung. In spleen and heart, those differences were less prominent,
although they are very appreciable. In blood, concentrations of free
cefotaxime were greater in rats without copper, but the differences
between concentrations are not as rough as in the others samples
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that have been analysed. So, the presence of copper is an influential
factor in the concentration of free cefotaxime.
This observation has been supported with the help of a statistical
analysis, here the means of concentrations of free cefotaxime, in
blood, liver, spleen, lung, heart and kidney of rats without copper and
of the rats with it, at 30, 60, 90, 120, 150, 180 and 210 min. after
administration of this cephalosporin, have been compared. This
comparison has been done by means of a T distribution with p < 0.05.
Therefore, in all those times is dismissed the nule hypothesis
and the averages differences of cefotaxime concentrations were
statistically significant. As deduced from these differences between
the free cefotaxime concentration in rats with and without copper
did not happen randomly, so those differences in the concentration
could be due to the formation of antibiotic/metal complex, remaining
a lesser concentration of free cefotaxime.
3.2. Distribution of cefotaxime
Tables 1 and 2 show the greatest concentration of cefotaxime in
blood. In the assayed organs the concentration of this cephalosporin
is decreasing in the sense: Kidney > liver > lung > spleen > heart.
Therefore cefotaxime is mainly stored in kidney. This fact happened
in both groups, so we induced, the metal is not an influential factor
in the distribution of cefotaxime.
Table 1. Average concentrations (mg/mL) of free cefotaxime in rats
without copper
TIME (MIN)
SAMPLES 30 60 90 120 150 180 210
BLOOD 0.80 0.46 0.25 0.14 0.08 0.06 0.02
LIVER 6.03.10–5 2.68.10–5 2.16.10–5 1.71.10–5 1.42.10–5 1.37.10–5 1.24.10–5
SPLEEN 2.70.10–5 1.58.10–5 1.45.10–5 0.53.10–5 0.41.10–5 0.39.10–5 0.38.10–5
KIDNEY 24.2.10–5 18.1.10–5 10.6.10–5 5.90.10–5 5.01.10–5 4.81.10–5 3.17.10–5
LUNG 7.19.10–5 5.26.10–5 3.52.10–5 3.02.10–5 1.33.10–5 1.22.10–5 0.46.10–5
HEART 2.56.10–5 1.87.10–5 1.23.10–5 1.14.10–5 1.08.10–5 0.86.10–5 0.85.10–5
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Table 2. Average concentrations (mg/mL) of free cefotaxime in rats with
copper
TIME (MIN)
SAMPLES 30 60 90 120 150 180 210
BLOOD 0.65 0.48 0.25 0.12 0.06 0.05 0.03
LIVER 4.47.10–5 2.46.10–5 1.24.10–5 0.88.10–5 0.84.10–5 0.61.10–5 0.25.10–5
SPLEEN 2.59.10–5 1.49.10–5 0.95.10–5 0.50.10–5 0.35.10–5 0.27.10–5 0.23.10–5
KIDNEY 20.6.10–5 9.03.10–5 5.16.10–5 4.01.10–5 3.28.10–5 2.80.10–5 2.64.10–5
LUNG 3.93.10–5 3.46.10–5 2.57.10–5 2.16.10–5 1.24.10–5 1.01.10–5 0.26.10–5
HEART 1.61.10–5 1.39.10–5 1.21.10–5 0.98.10–5 0.87.10–5 0.66.10–5 0.29.10–5
3.3. Stability of cefotaxime
The decrease rate constants of the concentration of free
cefotaxime in treated and control rats are of first-order, according to
the best values of correlation coefficient. The absolute values of the
logarithmic of the observed constants K are shown in Table 4, where
the highest value of log K is in heart for the 2 groups of rats,
therefore the cefotaxime is more stable in heart than in the others
studied organs.
In rats without copper the stability of cefotaxime in organs is
decreasing in the sense: heart and liver > kidney and spleen > lung.
In rats with copper the stability is: heart > kidney > liver, spleen and
lung.
In blood it was observed the lowest stability of cefotaxime in the
2 groups of rats.
Therefore the highest and lowest stability were unaffected by the
presence of copper.
3.4. Activity of cefotaxime
It is not only important the presence of copper in the availability
of cefotaxime, but also the presence of the metal results to be crucial
in the effectiveness of the cephalosporin dosage administrated to the
VOL. 75 (2), 217-231, 2009               (CU)II IN VIVO INTERACTION WITH CEFOTAXIME
227
animals because of the decrease of the free cefotaxime concentration
due to the metal.
Table 3. Differences more significant in concentrations of free cefotaxime
between rats with copper and without it
SAMPLES TIME (MIN) P VALUE OF T
BLOOD 150 0.04 2.34
30 0.02 2.7
90 0.02 2.9
120 1.47.10–4 6.73
LIVER 150 0.02 2.8
180 1.57.10–3 4.68
210 6.36.10–8 18.9
90 7.27.10–3 3.57
150 0.02 2.9
SPLEEN 180 1.14.10–4 6.98
210 2.50.10–4 6.23
60 4.34.10–4 5.74
90 1.12.10–7 15.57
KIDNEY 120 5.10–4 5.61
150 5.46.10–3 3.77
180 4.88.10–4 5.64
30 4.93.10–5 7.86
60 1.39.10–4 6.8
LUNG 90 1.35.10–3 4.8
120 5.46.10–3 3.77
180 0.04 2.45
210 1.28.10–3 4.84
30 6.39.10–4 5.4
HEART 120 6.16.10–3 3.68
180 8.72.10–3 3.44
210 1.19.10–6 12.9
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Table 4. The absolute values of the logarithmic of the observed constant K
RATS WITHOUT COPPER RATS WITH COPPER
BLOOD 1.73 1.79
LIVER 2.16 1.86
SPLEEN 1.93 1.86
KIDNEY 1.93 1.93
LUNG 1.86 1.86
HEART 2.16 2.16
Copper would provoke a fall down of free cefotaxime to values
even below of those corresponding to the MIC (minimum inhibitory
concentration) to kill the microorganism that would cause the
infection, so that the activity of cefotaxime will decrease or even the
cephalosporin will not have activity in many cases. So, in poisoned
patients with copper, it is very important to bear in mind this fact
when they have to follow a course of treatment with Cefotaxime.
In order to determinate and compare the biological activity of the
complex, it was necessary to know the impact in the cell viability of
the free cefotaxime as well as the metal by it-self in the same
experimental conditions.
Dissolved copper in media culture has not a deleterious effect at
all on growing cells (data not shown) even a mM scale in the discs,
concluding that if the complex had any biological activity, it should
not be due to rests of metal in the complex.
The detailed results of the assays with cefotaxime are shown in
Table 5 and 6.
Shocking the B. subtilis CECT 356 strain (Table 5), which was
thought to be a not susceptible bacteria (1, 9), arose as the most
sensitive strain to cefotaxime, much more that even the well known
sensitive strains of E. coli used by us. However B. subtilis was not
sorted out in the past among the cefotaxime targeted species, perhaps
due to be not a clinical bacteria, we strongly ask to favour their use
as standard in sensitivity tests in the future.
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Table 5. Activity of cefotaxime against B. subtilis CECT 356 and E. coli CECT
434 and CECT 516
Concentration of Diameter of the
cefotaxime in Moles  halo in mm
16.5.10–6 47
3.3.10–6 32
B. subtilis CECT 356 1.65.10–6 33
0.82.10–6 31
0.33.10–6 25
0.655.10–6 21
1.125.10–6 16
E. coli CECT 434 0.062.10–6 16
0.031.10–6 15
0.012.10–6 12
0.655.10–6 22
E. coli CECT 516 0.062.10–6 18
0.031.10–6 16
0.012.10–6 14
Table 6. Activity of cefotaxime against S. aureus spp aureus CECT 239 and
CECT 435
Diameter of the halo in mm
TSA Media Agar-blood Media
Concentration S. aureus S. aureus spp S. aureus S. aureus
of cefotaxime spp aureus spp aureus spp aureus spp aureus
CECT 239 CECT 435 CECT 239 CECT 435
16.5.10–6 33 37 27 30
3.3.10–6 27 29 21 24
1.65.10–6 27 27 18 23
0.82.10–6 24 25 15 20
0.33.10–6 19 23 12 17
As expected, cefotaxime was active against E. coli studied (Table
5), but some differences would be observed: strikingly E. coli CECT
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434, described as standard of sensitivity likely was less affected than
E. coli CECT 516, used in resistance to metals.
In the S. aureus spp aureus cultures, two different media were
used: TSA and blood agar. The later provided an environment similar
in somewhat manner to the mammalian tissues, because is a protein-
rich medium containing cellular rests. cefotaxime was effective
against those strains of S. aureus spp aureus, but the sensitivity was
increased in the TSA cultures. It could be justified because an
antibiotic sequestration by protein binding occurred in the blood agar
medium. cefotaxime is reported to bind proteins, so the amount of
free antibiotic would be 27-38% reduced in the presence of proteins
(11). It means that the amount of functional antibiotic was lesser in
the blood agar. Our findings agreed the reported data, because the GIZ
in blood agar had mean values 25% smaller than in TSA cultures.
As observed in E. coli, the two strains assayed did not show the
same results regarding the level of sensitivity to cefotaxime. However
the experimental results were not enough to build statistical analysis,
it seemed, comparing the data of the E. coli and S. aureus spp aureus
strains, that the intensity of the antibiotic aggression could have a
strain dependent component in each of the sensitive species.
As above mentioned, the importance of this work is to know
whether the complex, antibiotic-metal has biological activity against
the strains of microorganisms studied.
The cefotaxime-copper complex (Table 5) had some activity
against B. subtilis CECT 356 and E. coli CECT 516 only at the highest
concentration used, being harmless at lower concentrations.
The results would induce misleading conclusions. Apparently,
there waas a moderate microbicide activity against the model species,
but a matter of scale should be addressed. cefotaxime was fully
active at μM concentrations or lower, whereas the complex derivate
required a concentration six orders of magnitude higher to affect
slightly the cell viability. The maximum concentration in vivo of
cefotaxime reported in adult patients with a normal renal function
is 55 μM (1,11), so the microbicide effect of the complex lacked of
a practical relevance in physiological terms.
Finally, we wish to warm about the clinical outcome of our finding:
antibiotic treatment based on cefotaxime in copper poisoned patients
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with a bacterial sickness would be completely counterproductive,
because the infecting microorganisms could progress without
opposition.
4. REFERENCES
1. Doadrio, A. L., Sotelo, J. B., Doadrio, J. C., Orenga, R. & Mayorga, A. (1994)
Toxic-ions catalyzed hidrolysis of Amoxicillin: HPLC Kinetic studies. Ecl.
Quim. 19: 37-47.
2. Cressman, W. A., Sugita, E. T., Dohisio, J. T. & Niebergal, P. J. (1996) Cupric
ion-catalyzed  hidrolysis of Penicillins: Mechanism and site of complexation.
J. Pharm Sci. 58: 1471-6.
3. Doadrio, A. L., Doadrio, J. C. & Iribarren, M. (1992) Metal-ions catalyzed
hydrolysis of Ampicillin: RPHPLC-IEXHPLC Kinetic studies. Ecl. Quim. 17:
41-52.
4. Doadrio, A. & Mirasierra, M. G. (1969) Determinación espectrofotométrica de
la Ampicilina como quelato cúprico. An. Real. Acad. Farm. 35: 115-31.
5. Doadrio, A. & Mirasierra, M.G. (1973). Determinación espectrofotométrica de
la Metampicilina como complejo cúprico. An. Real. Acad. Farm. 39: 183-91.
6. Mayorga, A. (1999) Interacción de metales tóxicos con Ceftriaxona: Complejos
con Cu y V. Unpublished master’s thesis, University Complutense, Madrid,
Spain.
7. Chi-Hua, S. & Hui-Po, W. (1988) Methods in the preparation of D-Phenylgly-
cine containg cefotaxime. J. Food and Drugs Anal. 6: 477-484.
8. Blanchard, J. (1981) Evaluation of the relative efficacy of various techniques
for deproteinizzing plasma samples prio to high-performance liquid Chroma-
tographic analysis. J. Chromatogr. 226: 455-60.
9. Jones, R. N. (1995) Cefotaxime and desacetylcefotaxime antimicrobial interac-
tions the clinical relevance of enhanced activity: a review. Diagn. Microbiol.
Infect. Dis. 22(1-2): 19-33.
10. Madrigal, P. (1999) Estudio in vivo de la interacción de Cobree y Vanadio con
Cefotaxima. Unpublished master’s thesis, University Complutense, Madrid,
Spain.
11. Patel, K. B., Nicolau, D. P., Nightingale, C. H. & Quintialini, R. (1995) Phar-
macokinetics of Cefotaxime in healthy volunteers and patients. Diagn. Micro-
biol. Infect. Dis. 22: 49-55.
12. Drug Informat American Hospital Formulary Service (AHFS). 92-124.
* Información de contacto:
Doctor Antonio L. Doadrio Villarejo.
Departamento de Química Inorgánica y Bioinorgánica. Facultad de Farmacia. UCM.
Plaza Ramón y Cajal, s/n. 28040. Madrid. España.
Telf: 91 394 17 89. Fax: 91 394 17 86
Email: antonio@ranf.com
